Olfactory dysfunction in LRRK2 G2019S mutation carriers

被引:51
|
作者
Saunders-Pullman, R. [1 ,2 ]
Stanley, K. [1 ]
Wang, C. [3 ]
San Luciano, M. [1 ]
Shanker, V. [1 ,2 ]
Hunt, A. [1 ]
Severt, L. [1 ]
Raymond, D. [1 ]
Ozelius, L. J. [4 ,5 ]
Lipton, R. B. [2 ]
Bressman, S. B. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA
[4] Mt Sinai Sch Med, Dept Genet, New York, NY USA
[5] Mt Sinai Sch Med, Dept Genom Sci & Neurol, New York, NY USA
关键词
FAMILIAL PARKINSONS-DISEASE; EARLY-ONSET; IDENTIFICATION; PATHOLOGY; HYPOSMIA; STAGE;
D O I
10.1212/WNL.0b013e318227041c
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Olfactory dysfunction is an established nonmotor feature of idiopathic Parkinson disease (PD), which may precede disease onset. Olfaction is likely disturbed in patients with PD with leucine-rich repeat kinase (LRRK2) G2019S mutations, although the degree of impairment is debated. It is also unclear whether mutation carriers who have not yet manifested with PD have olfactory disturbances. Methods: Thirty-one subjects with LRRK2 G2019S mutation-related PD (PD-manifesting carriers [PD-MC]), 30 subjects with PD without mutations (PD noncarriers [PD-NC]), 28 mutation carrier family members (nonmanifesting carriers [NMC]), and 46 controls completed the University of Pennsylvania Smell Identification Test (UPSIT). Generalized estimating equations were applied to determine whether olfactory score was associated with PD and LRRK2 mutation status. Results: As expected, having PD was associated with impaired olfaction regardless of LRRK2 mutation status. More importantly, however, impaired olfaction was increased overall in LRRK2 carriers both with and without PD, though the impairment was only present in a subset of NMCs. Compared to controls, the mean score was lower among NMC (difference = -3.518, p = 0.006), MC (difference = -7.677, p < 0.0001), and idiopathic PD (PD-NC) (difference = -13.810, p < 0.0001). Olfaction was better among MC (PD-MC) than non-LRRK2 PD (PD-NC) (difference = 6.13, p = 0.0012). Group differences from the continuous analysis were maintained in dichotomous analysis stratifying at 15th percentile for age and gender. Conclusion: Olfaction is impaired in LRRK2 G2019S-mutation related PD, although less overall than other PD. Further, olfaction is impaired in a subset of LRRK2 NMC, suggesting that olfaction may be a marker for development of PD in this group, and that longitudinal studies are warranted. Neurology (R) 2011; 77: 319-324
引用
收藏
页码:319 / 324
页数:6
相关论文
共 50 条
  • [1] Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?
    Saunders-Pullman, Rachel
    Mirelman, Anat
    Wang, Cuiling
    Alcalay, Roy N.
    Luciano, Marta San
    Ortega, Robert
    Raymond, Deborah
    Mejia-Santana, Helen
    Ozelius, Laurie
    Clark, Lorraine
    Orr-Utreger, Avi
    Marder, Karen
    Giladi, Nir
    Bressman, Susan B.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2014, 1 (09): : 670 - 678
  • [2] Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease
    Alcalay, Roy N.
    Mejia-Santana, Helen
    Mirelman, Anat
    Saunders-Pullman, Rachel
    Raymond, Deborah
    Palmese, Christina
    Caccappolo, Elise
    Ozelius, Laurie
    Orr-Urtreger, Avi
    Clark, Lorraine
    Giladi, Nir
    Bressman, Susan
    Marder, Karen
    PARKINSONISM & RELATED DISORDERS, 2015, 21 (02) : 106 - 110
  • [3] REM Sleep Behavior Disorder, as Assessed by Questionnaire, in G2019S LRRK2 Mutation PD and Carriers
    Saunders-Pullman, Rachel
    Alcalay, Roy N.
    Mirelman, Anat
    Wang, Cuiling
    Luciano, Marta San
    Ortega, Roberto A.
    Glickman, Amanda
    Raymond, Deborah
    Mejia-Santana, Helen
    Doan, Nancy
    Johannes, Brooke
    Yasinovsky, Kira
    Ozelius, Laurie
    Clark, Lorraine
    Orr-Utreger, Avi
    Marder, Karen
    Giladi, Nir
    Bressman, Susan B.
    MOVEMENT DISORDERS, 2015, 30 (13) : 1834 - 1839
  • [4] LRRK2 G2019S mutation does not contribute to Parkinson's disease in South India
    Vijayan, Bejoy
    Gopala, Srinivas
    Kishore, Asha
    NEUROLOGY INDIA, 2011, 59 (02) : 157 - 160
  • [5] G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice
    Novello, Salvatore
    Arcuri, Ludovico
    Dovero, Sandra
    Dutheil, Nathalie
    Shimshek, Derya R.
    Bezard, Erwan
    Morari, Michele
    NEUROBIOLOGY OF DISEASE, 2018, 120 : 21 - 33
  • [6] The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews
    Thaler, Avner
    Ash, Elissa
    Gan-Or, Ziv
    Orr-Urtreger, Avi
    Giladi, Nir
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (11) : 1473 - 1482
  • [7] A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype
    Pirkevi, C.
    Lesage, S.
    Condroyer, C.
    Tomiyama, H.
    Hattori, N.
    Ertan, S.
    Brice, A.
    Basak, A. N.
    NEUROGENETICS, 2009, 10 (03) : 271 - 273
  • [8] Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review
    Guedes, L. Correia
    Ferreira, J. J.
    Rosa, M. M.
    Coelho, M.
    Bonifati, V.
    Sampaio, C.
    PARKINSONISM & RELATED DISORDERS, 2010, 16 (04) : 237 - 242
  • [9] LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease
    Bouhouche, Ahmed
    Tibar, Houyam
    Ben El Haj, Rafiqua
    El Bayad, Khalil
    Razine, Rachid
    Tazrout, Sanaa
    Skalli, Asmae
    Bouslam, Naima
    Elouardi, Loubna
    Benomar, Ali
    Yahyaoui, Mohammed
    Regragui, Wafa
    PARKINSONS DISEASE, 2017, 2017
  • [10] The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy
    Cho, Jin-Whan
    Kim, Sung-Yeon
    Park, Sung-Sup
    Jeon, Beom S.
    JOURNAL OF CLINICAL NEUROLOGY, 2009, 5 (01): : 29 - 32